+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon



Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon



Infection and Immunity 66(5): 1962-1967



We have previously shown that prophylactic administration of the liposome-encapsulated immunomodulating agents muramyl tripeptide phosphatidylethanolamine (MTPPE) and gamma interferon (IFN-gamma) results in strongly increased survival of mice from a normally lethal septicemia with Klebsiella pneumoniae. It was anticipated that the treatment acts on macrophages and nonspecifically augments host resistance to various infections. In the present study, we provide evidence for a key role for T cells in host defense potentiation by the liposomal immunomodulators toward K. pneumoniae septicemia. It is shown that both CD4 and CD8 cells are important in immunomodulation, most likely due to production of IFN-gamma. Depletion of circulating IFN-gamma resulted in strong reduction of the antimicrobial host defense activation. Administration of interleukin-10 resulted in decreased antimicrobial host defense activation by liposomal immunomodulators. Moreover, administration of liposomal immunomodulators was shown to induce predominantly T-helper type 1 (Th1) cell populations in the spleen. These findings indicate that immunomodulation with liposomal MTPPE and IFN-gamma favors Th1 and NK cell activation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008914914

Download citation: RISBibTeXText

PMID: 9573076


Related references

Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. Journal of Infectious Diseases 171(2): 385-392, 1995

Modulation of Nonspecific Antimicrobial Resistance of Mice to "Klebsiella pneumoniae" Septicemia by Liposome-Encapsulated Muramyl Tripeptide Phosphatidylethanolamine and Interferon- Alone or Combined. The Journal of Infectious Diseases 171(2): 385-392, 1995

Effect of liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma on Klebsiella pneumoniae infection in T-cell-deficient mice and in vitro. Masihi, K N Infectious Disease and Therapy; Immunotherapy of infections: 225-234, 1994

Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamide. Antimicrobial Agents and ChemoTherapy 38(1): 147-150, 1994

Free versus liposome encapsulated muramyl tripeptide phosphatidylethanolamine in treatment of experimental klebsiella pneumoniae infection. Infection & Immunity 60(1): 95-101, 1992

Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice. Journal of Immunology 135(2): 1372-1377, 1985

Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. International Journal of Immunopharmacology 9(2): 141-150, 1987

Liposome encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of osteosarcoma. Cancer Bulletin 43(2): 127-132, 1991

Free verus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide and interferon-gamma in experimental infection with Listeria monocytogenes. Biotherapy 6(2): 113-124, 1993

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Anticancer Research 18(2a): 1015-1019, 1998

Effect of systemic immunotherapy with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine on lymphocyte locomotion through type I collagen. Proceedings of the American Association for Cancer Research Annual Meeting 35: 481, 1994

Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model. Infection and Immunity 59(1): 126-130, 1991

Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunology Immunotherapy. 40(1): 57-64, 1995

Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. International Journal of Cancer 38(4): 495-500, 1986

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma-A multicenter randomized double-blind study. Cancer Biotherapy. 10(2): 125-130, 1995